Department of Medical and Surgical Sciences for Mother, Child and Adult, University of Modena and Reggio Emilia, Azienda Ospedaliero Universitaria Policlinico, Modena, Italy.
Department of Oncology, Haematology and Respiratory Disease, Azienda Ospedaliero-Universitaria Policlinico, University of Modena and Reggio Emilia, Modena, Italy.
Menopause. 2021 Feb 1;28(3):263-270. doi: 10.1097/GME.0000000000001737.
BRCA carriers are recommended to undergo prophylactic risk-reducing salpingo-oophorectomy (RRSO). Possible adverse health impacts of RRSO, particularly when done before natural menopause, can reduce the long-term satisfaction with this risk-reducing strategy. The aim of this study was to prospectively evaluate the level of satisfaction of women undergoing RRSO, also in relation to some specific characteristics at RRSO.
A prospective cohort study was performed in the Modena Family Cancer Clinic of the University Hospital of Modena (Italy). All BRCA1/2 confirmed mutation carriers who decided to undergo RRSO were recruited between 2016 and 2019.
Fifty-five women (29 BRCA1 and 26 BRCA2) (mean age: 50.4 ± 7.7 years [range 35-79]) were included with a mean follow-up after RRSO of 660.9 days (1.8 years) (range 35-1,688 days) (median: 549 days). No intraepithelial (Serous Tubal Intraepithelial Carcinoma)/invasive cancers were found (0%) at RRSO. No vasomotor symptoms at 1 month after surgery were reported by 11/22 (50%) premenopausal women at RRSO. All women (100%) with new "RRSO-caused" vasomotor symptoms with no previous breast cancer initiated postmenopausal hormone therapy. At the final follow-up the satisfaction rate (0-100 visual analog scale points) of the participants was 96.4 ± 8.6 points (range 62-100). To the question "Would you undergo RRSO again if it was proposed today? (0-100 visual analog scale points)" the answer was 99.4 ± 3.2 points (range 79-100). These scores were in general very high and did not change in the different groups according to pre/postmenopausal status at RRSO, cancer survivors versus healthy women at RRSO, BRCA status, hormone therapy users/nonusers after RRSO, "RRSO-caused" symptoms versus not RRSO-caused (P > 0.05).
Findings from this prospective study suggest that satisfaction with RRSO is very high and little dependent on the participants' characteristics at surgery. Women at high risk for ovarian cancer are very satisfied with their choice of risk-reduction strategy.
BRCA 携带者被建议进行预防性降低风险的输卵管卵巢切除术（RRSO）。RRSO 可能带来的不良健康影响，特别是在自然绝经前进行时，会降低对这种降低风险策略的长期满意度。本研究旨在前瞻性评估接受 RRSO 的女性的满意度，也与 RRSO 时的一些特定特征有关。
这是一项在意大利摩德纳大学医院摩德纳家庭癌症诊所进行的前瞻性队列研究。所有决定接受 RRSO 的 BRCA1/2 确诊突变携带者均于 2016 年至 2019 年期间招募。
55 名女性（29 名 BRCA1 和 26 名 BRCA2）（平均年龄：50.4±7.7 岁[范围 35-79]）入组，RRSO 后平均随访 660.9 天（1.8 年）（范围 35-1688 天）（中位数：549 天）。RRSO 时未发现上皮内（输卵管上皮内癌）/浸润性癌（0%）。RRSO 时，22 名绝经前女性中有 11 名（50%）报告术后 1 个月无血管舒缩症状。所有（100%）有新的“RRSO 引起”血管舒缩症状且无先前乳腺癌的女性均开始接受绝经后激素治疗。在最终随访时，参与者的满意度评分（0-100 视觉模拟评分点）为 96.4±8.6 分（范围 62-100）。对于“如果今天再次提议 RRSO，您是否会再次进行？（0-100 视觉模拟评分点）”这个问题，答案是 99.4±3.2 分（范围 79-100）。这些评分普遍非常高，并且根据 RRSO 时的绝经前后状态、RRSO 时的癌症幸存者与健康女性、BRCA 状态、RRSO 后激素治疗的使用/不使用、“RRSO 引起”的症状与非“RRSO 引起”的症状，在不同组中没有变化（P＞0.05）。
这项前瞻性研究的结果表明，RRSO 的满意度非常高，并且与手术时参与者的特征关系不大。患有卵巢癌高风险的女性对其降低风险策略的选择非常满意。
